Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.

R. Simoni, R. Cavalieri, G. Coppola, L. Ricciotti, O. De Pità, D. Criscuolo, A. Covelli, G. Papa, F. Mandelli

Research output: Contribution to journalArticlepeer-review


This study was designed to evaluate the efficacy and tolerability of recombinant leukocyte interferon alfa-2a (Hoffmann-LaRoche) as single agent in patients with histologically confirmed Mycosis Fungoides. The protocol consisted of a 12 week induction with subcutaneous interferon, escalating from 3 up to 18 million units daily, and a 6 or 9 month maintenance phase for complete or partial responses, respectively, with 18 million units 3 times weekly. 12 patients are evaluable: 5 are in complete remissions, 6 are partial remissions, and one had disease progression. Alfa-2a interferon was well tolerated: only 3 patients had WHO grade IV organ toxicity. Our study documents that recombinant leukocyte alfa 2a is a highly active agent in untreated patients with Mycosis Fungoides. Finally, the dose schedule chosen in this study allows alfa-2a interferon administration on an outpatient basis.

Original languageEnglish
Pages (from-to)93-99
Number of pages7
JournalJournal of Biological Regulators and Homeostatic Agents
Issue number2
Publication statusPublished - Apr 1987

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Endocrinology
  • Physiology
  • Immunology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)


Dive into the research topics of 'Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.'. Together they form a unique fingerprint.

Cite this